International Circulation:  The issue of light drug-eluting stent thrombosis has been a difficult and perplexing issue for doctors.  Has there been any new progress about the issue since 2006? 

David Holmes:  Now we know much more about it.  We know now about the importance of prolonged dual anti-platelet therapy and we are beginning to learn about the differences of genetic differences in people in terms of dual anti-platelet therapy.  We also now have a whole bunch of new drugs， for example prasugrel， which looks like over the long term will decrease stent thrombosis， albeit at a cost.  There is of course an economic cost， as well as a potential bleeding cost.  Those things that we have learned are the importance of dual anti-platelet therapy and we are learning more about the importance of testing for platelet responsiveness and platelet aggregation.